Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel in Previously Treated Advanced NSCLC
NCT01438307Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Sep 2011
- Primary completion
- Sep 2014
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cabazitaxel ginsenoside liposome injection in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Objective Response Rate at 28 months. Started Sep 2011; status: completed.
02
Drugs
cabazitaxel ginsenoside liposome injection
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01438307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01438307.